Safety Study of MT-4666 in Subjects With Alzheimer's Disease

Summary

The objective of this study is to evaluate the safety and efficacy of 2 fixed dose of MT-4666 administered once daily for 52 weeks with or without receiving a concomitant acetylcholinesterase inhibitors (AChEIs), in patients with mild to moderate Alzheimer's Disease (AD).

Timeline

Start

2014-12

Primary completion

2015-09

Completion

2015-10

Drugs

Indications